NCAM1 and breast cancer: In conclusion, this study identified CD56 as predictive biomarker for breast cancer sensitivity to NK-92-mediated cytotoxicity and as new regulator of the NK-immune function by enhancing the interaction between NK and breast cancer cells and thereby inducing immune synapse formation and stabilization.